biostudies-literatureXue SNIDA NIH HHSSeventh Framework ProgrammeNational Institute on Drug Abuse1686-1689https://www.ebi.ac.uk/biostudies/studies/S-EPMC6231713biostudies-literatureUnknown54(14)A nicotine-degrading enzyme termed NicA2 was altered (NicA2-J1) through fusion of an albumin binding domain to increase its half-life. Examination of NicA2-J1 in vivo demonstrated a complete blockade of brain nicotine access, which in turn blunted nicotine's psychoactive effects. These data further support development of pharmacokinetic nicotine cessation therapeutics.Chemical communications (Cambridge, England)An enzymatic advance in nicotine cessation therapy.PMC6231713R21 DA041839R21 DA036691623155DA036691DA041839Miranda POJanda KDXue SKallupi MZhou BGeorge OSmith LCfalseAn enzymatic advance in nicotine cessation therapy.A nicotine-degrading enzyme termed NicA2 was altered (NicA2-J1) through fusion of an albumin binding domain to increase its half-life. Examination of NicA2-J1 in vivo demonstrated a complete blockade of brain nicotine access, which in turn blunted nicotine's psychoactive effects. These data further support development of pharmacokinetic nicotine cessation therapeutics.2018-01-01T00:00:00Z2018 Feb2025-04-04T02:04:46.779Z2020-10-29T10:28:04ZS-EPMC62317132930879910.1039/c7cc09134f